These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 21182150

  • 21. Drug utilization studies within the VIDEOFAR project.
    Maggini M, Menniti Ippolito F, Spila Alegiani S, Traversa G, Fortini M.
    Ann Ist Super Sanita; 1991; 27(2):201-6. PubMed ID: 1755571
    [Abstract] [Full Text] [Related]

  • 22. [Comparative organization of drug monitoring in France and 7 European countries].
    Vaissere J, de Cremiers F, Auriche M, Juillet Y.
    Therapie; 1986; 41(5):369-74. PubMed ID: 3810527
    [No Abstract] [Full Text] [Related]

  • 23. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk.
    Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527
    [No Abstract] [Full Text] [Related]

  • 24. [Unwanted drug interactions. Keeping up pharmacovigilance using databases].
    Schindler B.
    Med Monatsschr Pharm; 2008 Apr; 31(4):155-6. PubMed ID: 18497254
    [No Abstract] [Full Text] [Related]

  • 25. Issues with regulatory pharmacovigilance in East European countries: the industry perspective.
    Hanzl-Dujmović I, Sulić-Milisić Z, Staresinić-Sernhorst I.
    Toxicol Lett; 2007 Feb 05; 168(3):228-35. PubMed ID: 17161561
    [Abstract] [Full Text] [Related]

  • 26. European perspective on risk management and drug safety.
    Raine J, Wise L, Blackburn S, Eichler HG, Breckenridge A.
    Clin Pharmacol Ther; 2011 May 05; 89(5):650-4. PubMed ID: 21512526
    [Abstract] [Full Text] [Related]

  • 27. [Discussion on methods of sample size estimation in conducting clinical reevaluation of postmarketing Chinese medicine].
    Tian F, Fu Y, Xie Y.
    Zhongguo Zhong Yao Za Zhi; 2011 Apr 05; 36(8):1097-102. PubMed ID: 21809593
    [Abstract] [Full Text] [Related]

  • 28. From electronic medical record to personal health records: present situation and trends in European Union in the area of electronic healthcare records.
    Iakovidis I.
    Stud Health Technol Inform; 1998 Apr 05; 52 Pt 1():suppl 18-22. PubMed ID: 10384547
    [Abstract] [Full Text] [Related]

  • 29. [The safety of drugs].
    de Cea Lavech de Chancy H.
    Rev Clin Esp; 1990 Sep 05; 187(4):184-90. PubMed ID: 2091076
    [Abstract] [Full Text] [Related]

  • 30. Implementation of SNOMED CT to the medicines database of a general hospital.
    Farfán Sedano FJ, Terrón Cuadrado M, García Rebolledo EM, Castellanos Clemente Y, Serrano Balazote P, Gómez Delgado A.
    Stud Health Technol Inform; 2009 Sep 05; 148():123-30. PubMed ID: 19745242
    [Abstract] [Full Text] [Related]

  • 31. Scientific challenges in postmarketing surveillance of ocular adverse drug reactions.
    Fraunfelder FW, Fraunfelder FT.
    Am J Ophthalmol; 2007 Jan 05; 143(1):145-149. PubMed ID: 17188050
    [Abstract] [Full Text] [Related]

  • 32. Design and functional specification of the Synapses federated healthcare record server. Synapses Consortium.
    Hurlen P, Skifjeld K.
    Stud Health Technol Inform; 1997 Jan 05; 43 Pt A():334-8. PubMed ID: 10179567
    [Abstract] [Full Text] [Related]

  • 33. Use of health care databases in pharmacoepidemiology.
    Hennessy S.
    Basic Clin Pharmacol Toxicol; 2006 Mar 05; 98(3):311-3. PubMed ID: 16611207
    [Abstract] [Full Text] [Related]

  • 34. Revised ADR report permits internal review of drug experience.
    Jeffrey LP.
    Pharm Times; 1986 Dec 05; 52(12):48-50. PubMed ID: 10317827
    [No Abstract] [Full Text] [Related]

  • 35. Communicating the risks of medicines: time to move forward.
    Dal Pan GJ.
    Med Care; 2012 Jun 05; 50(6):463-5. PubMed ID: 22581011
    [No Abstract] [Full Text] [Related]

  • 36. Early postmarketing drug safety surveillance: data mining points to consider.
    Hauben M.
    Ann Pharmacother; 2004 Oct 05; 38(10):1625-30. PubMed ID: 15304626
    [Abstract] [Full Text] [Related]

  • 37. Design considerations in an active medical product safety monitoring system.
    Gagne JJ, Fireman B, Ryan PB, Maclure M, Gerhard T, Toh S, Rassen JA, Nelson JC, Schneeweiss S.
    Pharmacoepidemiol Drug Saf; 2012 Jan 05; 21 Suppl 1():32-40. PubMed ID: 22262591
    [Abstract] [Full Text] [Related]

  • 38. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL.
    J Natl Cancer Inst; 2005 Jun 15; 97(12):872-3. PubMed ID: 15956645
    [No Abstract] [Full Text] [Related]

  • 39. Sample size for post-marketing safety studies based on historical controls.
    Wu YT, Makuch RW.
    Pharmacoepidemiol Drug Saf; 2010 Aug 15; 19(8):869-75. PubMed ID: 20572025
    [Abstract] [Full Text] [Related]

  • 40. DebugIT for patient safety - improving the treatment with antibiotics through multimedia data mining of heterogeneous clinical data.
    Lovis C, Colaert D, Stroetmann VN.
    Stud Health Technol Inform; 2008 Aug 15; 136():641-6. PubMed ID: 18487803
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.